CST9L

Across TCGA pan-cancer cohorts, CST9L mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CST9L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CST9L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CST9L is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where CST9L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CST9L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.984	<.001	10	view →
LUAD	All	III,IV	−1.302	<.001	9	view →
HNSC	Male	II,III,IV	+0.400	.013	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

CST9L–CCRCC

Open the CCRCC breakdown →